BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:58 PM
 | 
Mar 31, 2009
 |  BC Extra  |  Top Story

Genzyme, Bayer in cancer, MS deal

Genzyme (NASDAQ:GENZ) agreed to acquire the hematologic cancer portfolio of Bayer (Xetra:BAY). The deal, which could be worth as much as $2.9 billion, includes worldwide rights to Campath alemtuzumab, which is marketed for B cell chronic lymphocytic lymphoma (B CLL) and which the companies have been developing for multiple sclerosis.

Genzyme also gains Leukine sargramostim for acute myelogenous leukemia (AML) and Fludara fludarabine...

Read the full 324 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >